Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DMT210 Topical Gel
DMT210 · 1 trial · 1 indication
Change from baseline in ADSI score between Vehicle and 5% gel
| Arm | Type | Description |
|---|---|---|
| DMT210 Topical Gel | EXPERIMENTAL | DMT210 Topical Gel 5% applied to target lesion twice daily |
| Vehicle Control | PLACEBO_COMPARATOR | Topical Gel vehicle applied to target lesion twice daily |
| Name | Type | Description |
|---|---|---|
| DMT210 Topical Gel | DRUG | DMT210 Topical Aqueous Gel 5% applied twice daily |
| Vehicle Control | DRUG | Topical Vehicle Gel applied twice daily |
Inclusion Criteria: * Male or female 12 years or older * Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement * Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas * Patie...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, Lutikizumab |
| Pfizer Inc. | PFE | 10 | PHASE3 | Abrocitinib, PF-08049820, PF-07275315, PF-07264660, PF-07832837 |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab, Dupilumab SAR231893, Dupilumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | dupilumab, REGN20423 |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777, APG990 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632, GHZ339 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | Bempikibart |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-7624 |
DMT210 is an investigational small molecule topical gel developed by Dermata Therapeutics, Inc. for the treatment of atopic dermatitis. It is also known as DMT210 Topical Gel. The product is designed to be applied to the skin and is being studied as a potential therapy for inflammatory skin disease.
DMT210 is being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is formulated as a topical gel applied directly to affected skin. The only completed clinical study of DMT210 enrolled patients with atopic dermatitis, and the drug remains investigational rather than approved for any use.
DMT210 is being developed by Dermata Therapeutics, Inc., a dermatology-focused biopharmaceutical company that trades under the ticker symbol DRMA. Dermata is the sponsor of the clinical program evaluating DMT210 Topical Gel in atopic dermatitis.
DMT210 is in Phase 2 clinical development. One Phase 2 trial of DMT210 Topical Gel in atopic dermatitis has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
DMT210 has been studied in one completed Phase 2 trial, NCT02949960, titled DMT210 Topical Gel in the Treatment of Atopic Dermatitis. The trial enrolled 19 participants aged 12 years and older in the United States. It was randomized, double-blind, and placebo-controlled, and it is no longer recruiting.
Yes. DMT210 and DMT210 Topical Gel refer to the same investigational product from Dermata Therapeutics. The full name reflects its topical gel formulation, which is the dosage form used in the completed Phase 2 atopic dermatitis study NCT02949960.